Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Update

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) saw a large decline in short interest in February. As of February 13th, there was short interest totaling 27,138 shares, a decline of 85.9% from the January 29th total of 192,649 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

Hansa Biopharma AB (publ) Trading Down 36.7%

Shares of Hansa Biopharma AB (publ) stock traded down $1.68 during midday trading on Wednesday, hitting $2.90. 350 shares of the company traded hands, compared to its average volume of 10,133. The firm’s fifty day moving average price is $2.91 and its 200-day moving average price is $3.20. Hansa Biopharma AB has a 12 month low of $2.73 and a 12 month high of $4.58.

Analyst Upgrades and Downgrades

HNSBF has been the topic of several analyst reports. Jefferies Financial Group initiated coverage on shares of Hansa Biopharma AB (publ) in a research report on Wednesday, October 29th. They set a “buy” rating on the stock. Wedbush started coverage on Hansa Biopharma AB (publ) in a research note on Wednesday, January 7th. They set an “outperform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Hansa Biopharma AB (publ) in a report on Thursday, February 12th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.